Your web browser is out of date.

For your security and improved experience online, please update your browser.

Diabetes on the Net is intended for healthcare professionals

Resources

Boehringer Ingelheim and
Lilly Alliance

on-demand video

Play Video

Going beyond type 2 diabetes: the multiple cardiovascular, renal and metabolic benefits of Jardiance® (empagliflozin)

This promotional video presentation was originally broadcast on 19 November 2021. Please note that the speakers are not able to answer questions from attendees watching the video on-demand.

The Boehringer Ingelheim and Lilly Alliance has provided the funding for this sponsored session, including speaker honoraria and presentation support where applicable. Boehringer Ingelheim and Lilly Alliance products are discussed during this session.

Prescribing Information and adverse event reporting for Jardiance® (empagliflozin) can be accessed by clicking on the links
Great Britain     Northern Ireland

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).

Resources

Resources for online viewing only.

Lyumjev® is indicated for the treatment of diabetes mellitus in adults only.
Lymjev in not indicated for use in children.

Trulicity is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
• as monotherapy when metformin is considered inappropriate due to intolerance or contraindications.
• in addition to other medicinal products for the treatment of diabetes mellitus

Company profile

In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance that centres on compounds representing several of the largest diabetes treatment classes. Depending on geographies, the companies either co-promote or separately promote the respective molecules each contributing to the alliance. The Alliance leverages the strengths of two of the world’s leading pharmaceutical companies to focus on patient needs. By joining forces, the companies demonstrate their commitment, not only to the care of people with diabetes, but also to investigating the potential to address areas of unmet medical needs

This content is for UK Healthcare Professionals only. This resource page and the materials included have been organised and supported by the Boehringer Ingelheim and Lilly Alliance.

PC-GB-105506 November 2021

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.